Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert Trooskens

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2016
WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based TherapyLinda J W Bosch, Yanxin Luo, Victoria V Lao, et al.
The Journal of Investigative Dermatology|August 1, 2025
Comprehensive Analysis of the Melanoma DNA Methylome Identifies LY75 Methylation as an Independent Marker Predicting Poor Clinical OutcomeKarin van den Hurk, Kim Lommen, Louis Coussement, et al.
European Urology|April 25, 2016
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk ScoreLeander Van Neste, Rianne J Hendriks, Siebren Dijkstra, et al.
Oncotarget|October 4, 2017
<i>Decoy receptor 1</i> (<i>DCR1)</i> promoter hypermethylation and response to irinotecan in metastatic colorectal cancerLinda J W Bosch, Geert Trooskens, Petur Snaebjornsson, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2016
WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based TherapyLinda J W Bosch, Yanxin Luo, Victoria V Lao, et al.
The Journal of Investigative Dermatology|August 1, 2025
Comprehensive Analysis of the Melanoma DNA Methylome Identifies LY75 Methylation as an Independent Marker Predicting Poor Clinical OutcomeKarin van den Hurk, Kim Lommen, Louis Coussement, et al.
European Urology|April 25, 2016
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk ScoreLeander Van Neste, Rianne J Hendriks, Siebren Dijkstra, et al.
Oncotarget|October 4, 2017
<i>Decoy receptor 1</i> (<i>DCR1)</i> promoter hypermethylation and response to irinotecan in metastatic colorectal cancerLinda J W Bosch, Geert Trooskens, Petur Snaebjornsson, et al.
Pageof 3